• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cumberland Pharmaceuticals Inc.

    3/10/25 5:01:01 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPIX alert in real time by email
    DEFA14A 1 a2024proxy-defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934
    Filed by the Registrant þ
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    o  Preliminary Proxy Statement
    o  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o  Definitive Proxy Statement
    þ  Definitive Additional Materials
    o  Soliciting Material Pursuant to §240.14a-12
    CUMBERLAND PHARMACEUTICALS INC.

    Payment of Filing Fee (Check the appropriate box):

    þ  No fee required.
    o  Fee paid previously with preliminary materials
    o  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    1


    cumberlandlogoa02a01a.jpg

    As a shareholder of Cumberland Pharmaceuticals Inc. you have the option of voting your shares electronically through the Internet, eliminating the need to return the proxy card. Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated and returned the proxy card. Votes submitted electronically over the Internet or by mobile device must be received by 11:59 p.m., Eastern Time, on April 21, 2025.
    Vote Your Proxy on the Internet:Vote Your Proxy on your Mobile:Vote Your Proxy via the mail:
    OROR
    Go to www.cstproxyvote.com
    Have your proxy card available when you access the above website. Follow the prompts to vote your shares.On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares.Mark, sign, and date your proxy card, then detach it, and return it in the postage-paid envelope provided.
    PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE
     VOTING ELECTRONICALLY OR BY PHONE

    ÚFOLD AND DETACH HERE AND READ THE REVERSE SIDE Ú

    PROXY
    This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this Proxy will be voted FOR Proposals 1 AND 2.
    xa01a.jpg
    ForAgainstAbstain
    1. For the election as directors of the nominees listed below, except to the extent that authority is specifically withheld.



    FOR all Nominees listed to the left
    WITHHOLD AUTHORITY to vote (except as marked to the contrary for all nominees listed to the left
    2. To ratify the appointment of Carr, Riggs & Ingram, L.L.C. as independent registered accounting firm of the Company for fiscal year ending December 31, 2025.
    ooo
    NOMINEES: (1) Dr. Gordon R. Bernard (2) Mr.Joseph C. Galante
    (3) Mr.A.J. Kazimi
    oo
    (INSTRUCTION: To withhold authority to vote for any individual nominee, write that nominee's name on the space provided below.)
    In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting.
    I understand that I may revoke this Proxy only by: (i) written instructions to that effect, signed and dated by me, which must be actually received by the Corporate Secretary prior to the commencement of the Annual Meeting; (ii) properly submitting to the Company a duly executed proxy bearing a later date; OR (iii) appearing at the Annual Meeting and voting in person.
    COMPANY ID:
    PROXY NUMBER:
    ACCOUNT NUMBER:
    Signature _________________________________ Signature if Held Jointly____________________________________ Date____________ , 2025.
    Please sign exactly as your name appears on your stock certificate. When shares are held by joint tenants, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. If the
    shares are owned by a corporation, sign in the full corporate name by the President or other authorized officer. If the shares are owned by a Partnership, sign in the name of the Partnership name by an authorized person.
    2









    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held April 22, 2025

    The Notice, Proxy Statement, and our Annual Report on Form 10-K for the year ended December 31, 2024 are available at:
    http://www.cstproxy.com/cumberlandpharma/2025





    ▼ FOLD AND DETACH HERE AND READ THE REVERSE SIDE ▼


    THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF
    CUMBERLAND PHARMACEUTICALS INC.
    NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
    To Be Held April 22, 2025

    The undersigned hereby appoints A.J. Kazimi and Kenneth J. Krogulski, or either of them, as proxies, with full power of substitution, and hereby authorizes each of them to represent and vote, as designated on the reverse side, all of the shares of Common Stock of Cumberland Pharmaceuticals Inc., held of record by the undersigned on February 28, 2025 at the Annual Meeting of Shareholders to be held at the Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203 on Tuesday, April 22, 2025, at 9:30 a.m. Central Time, or any adjournment(s) or postponement(s) thereof, with all powers which the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the instructions specified on the reverse side.

    THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTIONS ARE GIVEN, THIS PROXY WILL BE VOTED FOR ALL OF THE DIRECTOR NOMINEES NAMED IN PROPOSAL 1 ON THE REVERSE SIDE AS WELL AS PROPOSAL 2. THE PROXIES NAMED ABOVE ARE HEREBY AUTHORIZED TO VOTE IN THEIR DISCRETION UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY ADJOURNMENT(S) OR POSTPONEMENT(S) THEREOF.



    (Continued, and to be marked, dated and signed, on the other side)
    3
    Get the next $CPIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPIX
    Leadership Updates

    Live Leadership Updates

    See more
    • CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

      NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka.  Brown is an attorney at Adams and Reese LLP, a

      7/19/22 9:25:00 AM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Young Caroline bought $417 worth of shares (93 units at $4.48), increasing direct ownership by 0.29% to 32,485 units (SEC Form 4)

      4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

      5/9/25 5:05:15 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jones James bought $833 worth of shares (186 units at $4.48), increasing direct ownership by 0.43% to 43,000 units (SEC Form 4)

      4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

      5/9/25 5:04:26 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman and CEO Kazimi A J bought $833 worth of shares (186 units at $4.48), increasing direct ownership by 0.00% to 5,699,092 units (SEC Form 4)

      4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

      5/9/25 5:03:35 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Young Caroline bought $417 worth of shares (93 units at $4.48), increasing direct ownership by 0.29% to 32,485 units (SEC Form 4)

      4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

      5/9/25 5:05:15 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jones James bought $833 worth of shares (186 units at $4.48), increasing direct ownership by 0.43% to 43,000 units (SEC Form 4)

      4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

      5/9/25 5:04:26 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman and CEO Kazimi A J bought $833 worth of shares (186 units at $4.48), increasing direct ownership by 0.00% to 5,699,092 units (SEC Form 4)

      4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

      5/9/25 5:03:35 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

      SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

      2/9/24 5:27:23 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

      SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

      2/10/23 5:01:42 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

      SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

      2/14/22 5:17:27 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

      Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients. The analysis evaluated the safety and efficacy of Caldolor for the management of pain and fever in patients 60 years of age and older. It marks an important advancement in pain management for older individuals, as it's one of the first studies specifically evaluating Caldolor in this vulnerable population.

      5/27/25 4:05:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

      NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million. Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabil

      5/6/25 4:05:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

      NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. Once registered, participants can dial in from their phone using a dial-in and PIN nu

      4/29/25 4:05:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPIX
    Financials

    Live finance-specific insights

    See more
    • NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

      Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients. The analysis evaluated the safety and efficacy of Caldolor for the management of pain and fever in patients 60 years of age and older. It marks an important advancement in pain management for older individuals, as it's one of the first studies specifically evaluating Caldolor in this vulnerable population.

      5/27/25 4:05:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

      NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million. Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabil

      5/6/25 4:05:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

      NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. Once registered, participants can dial in from their phone using a dial-in and PIN nu

      4/29/25 4:05:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cumberland Pharmaceuticals Inc.

      10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

      5/9/25 5:01:27 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

      5/6/25 5:02:00 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

      4/28/25 3:38:30 PM ET
      $CPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care